Taro must face US antitrust claims over generics, states argue
( November 4, 2026, 15:29 GMT | Official Statement) -- MLex Summary: US states accusing Taro Pharmaceuticals of artificially inflating generic drug prices and reducing competition told a federal judge that a private class action settlement does not bar their claims. The states said that they were not parties to the settlement and none of their claims could have been raised by a private class.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.